Archive for August, 2022

  • Isofol provides update on the AGENT study

    GOTHENBURG, Sweden, August 31, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today announced that, having received access to…

    by
  • Isofol Medical AB (publ) publishes interim report, January–June 2022

    GOTHENBURG, Sweden, August 23, 2022 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's interim report…

    by
  • Invitation to presentation of Isofol´s report for the second quarter of 2022

    GOTHENBURG, Sweden, August 15, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (“Isofol”), will publish the company’s results for…

    by
  • Isofol Announces Topline Results of Phase III AGENT Study – Did Not Meet Primary or Key Secondary Endpoints

    GOTHENBURG, Sweden, August 3, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), today announced topline results that neither the…

    by